
    
      This is a Phase 2, open label, multicenter study of eflapegrastim in pediatric participants
      (â‰¥1 month to <18 years) with solid tumors or lymphoma.

      Approximately 40 participants will be enrolled and assigned to one of 4 age-based cohorts.
      Participants enrolled in Cohort 1 will be followed for dose-limiting toxicities (DLTs) prior
      to initiating parallel enrollment into Cohorts 2 through 4.

      All participants will receive chemotherapy as Standard of Care after which a subcutaneous
      (SC) dose of eflapegrastim will be administered up to 4 treatment cycles.
    
  